| Literature DB >> 35529469 |
Haitao Ma1, Xiaolong Li1, Hua Yang1, Yuan Qiu1, Weidong Xiao1.
Abstract
An ileostomy is a surgery that is commonly performed to protect low pelvic anastomoses or prevent high-risk anastomotic leakages. However, various postoperative complications remain of major concern. After an ileostomy, the distal intestinal segment is left open for an extended period and is in a non-functional state. Consequently, the intestinal mucosa, smooth muscle, and microbiota undergo significant changes that are closely related to postoperative recovery and complications. A systematic description of these changes is necessary to understand the relationship among them and take more effective measures for postoperative intervention.Entities:
Keywords: distal dysfunctional intestine; ileostomy; microbiota; mucosal barrier; probiotics
Year: 2022 PMID: 35529469 PMCID: PMC9072868 DOI: 10.3389/fnut.2022.842198
Source DB: PubMed Journal: Front Nutr ISSN: 2296-861X
FIGURE 1(A). Schematic diagram of an ileostomy. (B) Ileal tissue from an ileostomy reversal, there is a significant difference between the proximal and distal intestinal tissue by visual inspection. (C) Hematoxylin-eosin staining of proximal and distal intestinal tissues. There is a significant atrophy in distal intestinal mucosa.
FIGURE 2Differences between the functional proximal intestinal segment and the non-functional distal intestinal segment of an ileostomy. Compared with the proximal intestinal segment, fragile and atrophic intestinal villi, a significantly reduced number of goblet cells, thinned mucus layer, decreased Paneth cells with fewer antimicrobial peptides (AMPs), reduced mucosal bacterial load and microbial diversity, decreased intestinal interepithelial lymphocytes, aggregated innate immune cells (such as neutrophils), atrophic muscular layer and possible reduction of serotonin are shown in the distal intestinal segment.
The microbial metabolites and compositions associated with human systems.
| System | Microbial related substances | Disease (references) |
| Circulatory system | Lipopolysaccharides (LPS), trimethylamine (TMA), bile acids, short-chain fatty acids (SCFAs), phenylacetic acid, p-cresyl sulfate, indoxyl sulfate, anthocyanins, phytoestrogens | Cardiovascular disease ( |
| Motor system | SCFAs, LPS medium chain fatty acids (MCFAs), tryptophan and tryptophan-derived metabolites, polyamines, TMA | Spondyloarthritis ( |
| Endocrine system | SCFAs, γ-aminobutyric acid (GABA), circulating branched-chain amino acids (BCAAs), serotonin (5-HT), other neurotransmitters (NTs), LPS, trimethylamine N-oxide (TMAO), tryptophan-derived indoles, bile acids | Obesity ( |
| Nervous system | SCFAs, GABA, 5-HT, other NTs, amyloids, LPS, histamine, dopamine, endotoxin, hydrogen, hydrogen sulfide (H2S), indoleacetic acid | Alzheimer’s Disease ( |
| Digestive system | LPS, SCFAs, urolithins, bile acids, tryptophan, succinate, ethanol, H2S, polyamines, toxins | Cancer ( |
| Urinary system | Tryptophan, SCFAs, LPS, TMAO, Phenols, indole | Kidney disease ( |
| Respiratory system | LPS, SCFAs, microbe-associated molecular patterns | Chronic Obstructive, Pulmonary Disease, Asthma, Cystic Fibrosis ( |